At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Enhancement of Post-stroke Neural Plasticity With Atomoxetine: a Pilot Study
In Brief
A Phase 2 clinical trial evaluating Atomoxetine and Placebo for Atomoxetine Hydrochloride and Placebos. Completed, enrolled 12 participants.
Detailed Summary
This proposal evaluates the safety and effectiveness of a noradrenergic drug named atomoxetine combined with motor training to enhance cortical plasticity and improve hand function after stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtomoxetine Hydrochloride, Placebos
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
Primary CompletionDec 2012
Study CompletionDec 2014
First PostedJun 2016
TodayJul 2026
First PostedJun 2, 2016
Enrollment StartNov 1, 2006
Primary CompletionDec 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 10.1 years ago
Interventions
Atomoxetinedrug
Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Placebodrug
Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.